Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Altimmune Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ALT
Nasdaq
2834
https://altimmune.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Altimmune Inc
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 27th, 2024 11:00 am
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
- Mar 20th, 2024 11:30 am
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
- Jan 2nd, 2024 12:30 pm
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
- Nov 30th, 2023 9:24 pm
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
- Nov 7th, 2023 12:00 pm
Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
- Oct 31st, 2023 11:30 am
Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
- Oct 26th, 2023 11:30 am
Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023
- Oct 25th, 2023 11:30 am
Altimmune to Participate at Two Upcoming Investor Conferences
- Oct 17th, 2023 11:30 am
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
- Sep 26th, 2023 11:30 am
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
- Sep 12th, 2023 11:30 am
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
- Aug 10th, 2023 11:00 am
Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
- Aug 3rd, 2023 11:30 am
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
- Aug 1st, 2023 11:30 am
These 2 ‘Strong Buy’ Penny Stocks Could Soar to $25 (Or Higher), Says Piper Sandler
- Jun 27th, 2023 1:56 pm
Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023
- Jun 16th, 2023 11:30 am
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023
- Jun 15th, 2023 11:30 am
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
- May 11th, 2023 11:00 am
Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
- May 4th, 2023 11:30 am
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B
- Apr 11th, 2023 11:30 am
Scroll